#ICAD INC SKIN#
#ICAD INC FREE#

#ICAD INC SKIN#

Therefore, hospitals are preferred over ambulatory surgical centers and specialty clinics in the non-melanoma skin cancer treatment market. The treatment modalities for non-melanoma skin cancer usually require expensive radiation therapy. The attractiveness index of basal cell carcinoma is 1.5, considerably larger than the 0.5 of squamous cell carcinoma during the same period.Д®nd User вЂ“ Hospitals Popular Channel in the Non-Melanoma Skin Cancer Treatment Market thrice the size of the former by end 2025. Get A Customized Scope To Match Your Need Ask An Expert вЂ“ вЂ“ Basal Cell Carcinoma Dominates the Non-Melanoma Skin Cancer Treatment MarketД®ven though squamous cell carcinoma is predicted to record a higher CAGR of 6.4% from 2017-2025, it is unlikely to outpace basal cell carcinoma anytime soon as the latter is likely to value at approx. Within radiation therapy, companies may wish to target superficial radiation therapy. Radiation therapy is poised to be worth more than US$ 4.7 BnВ by end 2025. Radiation therapy is larger than chemotherapy andВ photodynamic therapyВ combined, making it imperative for key stakeholders in the non-melanoma skin cancer treatment market to focus on this treatment type. Treatment Type вЂ“ Radiation Therapy Larger than Chemotherapy and Photodynamic Therapy Non-melanoma skin cancer is more prevalent in senior citizens and the Population Reference Bureau estimates that Americans over the age of 65 will double to almost 100 million by 2060. North America is estimated to hold a market share of roughly 55% in the global non-melanoma skin cancer treatment market in 2017 and is anticipated to have the highest attractiveness index of 3.0 during the forecast period.

Region вЂ“ High Prevalence of Non-Melanoma Skin Cancer in North America Have feedback on this article? Concerned about the content? Get in touch with us directly.Get Going With Sample Of Non-Melanoma Skin Cancer Market Report! Simply Wall St has no position in any stocks mentioned. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. This article by Simply Wall St is general in nature.

#ICAD INC FREE#

Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Management Team: An experienced management team on the helm increases our confidence in the business вЂ“ take a look at who sits on iCAD's board and the CEOвЂ™s background. Historical Track Record: What has iCAD's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity. We've also compiled a list of pertinent factors you should look at: There are too many aspects of iCAD to cover in one brief article, but the key fundamentals for the company can all be found in one place вЂ“ iCAD's company page on Simply Wall St. It turns out an average annual growth rate of 71% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. So, the company is predicted to breakeven approximately 2 years from now. They expect the company to post a final loss in 2021, before turning a profit of US$4.9m in 2022. The most pressing concern for investors is iCAD's path to profitability вЂ“ when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.ДЄccording to the 5 industry analysts covering iCAD, the consensus is that breakeven is near. The US$242m market-cap company posted a loss in its most recent financial year of US$14m and a latest trailing-twelve-month loss of US$21m leading to an even wider gap between loss and breakeven. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. ( NASDAQ:ICAD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company.

Icad inc